The Medicines Patent Pool’s patents and licences database MedsPaL is a free resource that provides information on the intellectual property status of key health technologies and products.
The Medicines Patent Pool (MPP)’s patents and licences database MedsPaL is a free resource that provides information on the intellectual property status of the following key health technologies and products:
Medicines: Patented medicines on the Model lists of Essential Medicines of the World Health Organisation (WHO EML), medicines prioritised for MPP licensing and possible future priority medicines as identified by WHO and other public health stakeholders, in low- and middle-income countries.
Vaccines: Selected COVID-19 vaccines and vaccines used for the prevention of mpox. Content will evolve to cover other key patented vaccines for health emergencies.
Technologies: A selection of long acting technologies used for extended release of pharmaceuticals, from LAPaL, another free online resource coordinated by MPP.
MedsPaL was launched in October 2016 focusing on medicines for three diseases: HIV, hepatitis C and tuberculosis. In December 2017, it was expanded to cover all patented medicines on the World Health Organization Model List of Essential Medicines (WHO EML).
MedsPaL was further expanded in 2020 to include patent information on treatments being tested for COVID-19. In 2024, MedsPaL’s interface received a new design with enhanced content and tools. This new version provides additional information on vaccines for health emergencies, long-acting health technologies, and includes medicines prioritised by MPP and other public stakeholders.
In 2025, the database contained searchable information on 208 health products. Patent information included a total of 32,240 national patent applications and 731 international applications.
We also collaborate with national and regional patent offices, to collect information for the database. See more
Access the MedsPaL Release Notes published in May 2024 when a new version of MedsPaL was launched.
09 Jun 2026
The World Health Organization supports initiatives that improve the transparency and accessibility of health-related intellectual property information. The updates to MedsPaL align with our goal to ensure that essential medical innovations are accessible to those who need them most, especially in LMICs.
Dr Yukiko Nakatani, Assistant Director-General, Access to Medicines and Health Products, the World Health Organization
May 2024
When UNDP Ukraine starts its medicines procurement process, we need as much as information as possible on patent status. For this, we use different sources, government of course but also international, MedsPaL is one of those sources that we consult from.
Dorin Rotaru, Health Programme Manager, UNDP, Ukraine
October 2016
We are regular users of MedsPaL and the launch of its updated platform is a welcome development for procurement agencies. It offers practical enhancements that will aid in the effective management of our medicine sourcing and supply chains. The ability to save searches and receive notifications, in particular, ensures that we are up to date with the latest patent information, which is vital for our procurement strategies.
Harm Veerkamp, Director, Procurement Services, IDA Foundation
When working to increase access to medicines, it is very important to understand patent status in country and any barriers to access. Communities are instrumental in advocating for the reduction of prices for HIV, TB and HCV medicines. In that sense MPP database on patents, MedsPaL, and its effort to increase transparency of patent information is instrumental to community groups working with TRIPS flexibilities.
Sergiy Kondratyuk, Project Manager, ITPC Global
January 2020
Users should NOT consider MedsPaL a complete and authoritative source of patent information, and it is not meant to provide a ‘freedom-to-operate’ analysis. It only provides a snapshot at a point in time, based on the information available to MPP.
We do not accept any legal responsibility for the accuracy of data. In particular, we do not guarantee it is complete, up to date or fit for specific purposes. Users should undertake additional country search and legal analysis before making any decision based on this data.
A full understanding of the patent situation in any country, for a specific vaccine, requires additional information and analysis not provided in this database. This includes an analysis of the specific claims of a national/regional patent application or granted patent.
14 Feb 2022
18 Apr 2023
24 Apr 2026
09 Jul 2025
21 Nov 2025
Access them all here | Register to MedsPaL updates
Newsletters & Updates » MedsPaL Newsletter
27 Apr 2026
15 Dec 2025
30 Jul 2025
MedsPaL Updates
subscribe to our MedsPaL Updates newsletter
The Medicines Patent Pool will use the information (email address) you provide on this form to be in touch with you and to provide updates.
You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at medspal@medicinespatentpool.org. We will treat your information with respect. For more information about our privacy practices, please visit our website. By clicking below, you agree that we may process your information in accordance with these terms.
We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp’s privacy practices here.
MedsPaL
- in English
- in French
LAPaL — Long-Acting Patents and Licences Database
AccessPaL - Access Pathways and Landscape tracker